Incyte (NASDAQ:INCY) shares gained for the second straight day Tuesday in the wake of positive data for its drug candidate ...

Additonally, the stock's price target was changed several times during the past month, ranging from $63 to $98. However, since Monday, shares of Incyte have jumped approximately 13%. It is worth ...

Incyte stock plummeted Tuesday as seasonality hacked at first-quarter revenue and profit with notable sales misses from blockbuster drug Jakafi and skin cream Opzelura. Please watch the video at ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Short interest for Incyte gives investors a sense of the degree to which investors are betting on the decline of Incyte's stock. Short interest data is updated every two weeks.

Incyte (INCY) TD Cowen analyst Marc Frahm maintained ... Jefferies also initiated coverage with a Buy rating on the stock with a $81.00 price target. See Insiders’ Hot Stocks on TipRanks ...

Mehta of the University of Michigan and co-authors. Incyte’s stock was strongly correlated with Medivation’s during the year ...

The stock trades 34% below our fair value estimate of $88 per share. Incyte has built a solid foundation over the past decade with hematology drug Jakafi, and the approval of the same active ...

Phase 2 studies of povorcitinib in PN, asthma and chronic spontaneous urticaria are also ongoing. About Incyte Dermatology Incyte’s science-first approach and expertise in immunology ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...